$ONXX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ONYX PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ONYX PHARMACEUTICALS INC. Get notifications about new insider transactions in ONYX PHARMACEUTICALS INC for free.
Page: < prev 1 2 3 4 5 6 7 ... 12 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Buy | M | 28.55 | 3,164 | 90,332 | 9,764 | 6.6 K to 9.8 K (+47.94 %) |
Apr 16 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Sell | S | 95.15 | 1,347 | 128,167 | 50,204 | 51.6 K to 50.2 K (-2.61 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 30.28 | 510 | 15,443 | 6,635 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 30.28 | 146 | 4,421 | 7,145 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 30.28 | 619 | 18,743 | 7,291 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 37.68 | 1,437 | 54,146 | 17,729 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 37.68 | 1,198 | 45,141 | 19,166 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 28.55 | 586 | 16,730 | 547 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 28.55 | 440 | 12,562 | 1,133 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 28.55 | 600 | 17,130 | 1,573 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 28.55 | 220 | 6,281 | 2,173 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 35.18 | 3,645 | 128,231 | 9,115 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 35.18 | 547 | 19,243 | 12,760 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Sell | S | 95.00 | 6,618 | 628,710 | 19,374 | 26 K to 19.4 K (-25.46 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 28.55 | 586 | 16,730 | 25,992 | 25.4 K to 26 K (+2.31 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 35.18 | 3,645 | 128,231 | 25,406 | 21.8 K to 25.4 K (+16.75 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 37.68 | 1,437 | 54,146 | 21,761 | 20.3 K to 21.8 K (+7.07 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 28.55 | 440 | 12,562 | 20,324 | 19.9 K to 20.3 K (+2.21 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 30.28 | 510 | 15,443 | 19,884 | 19.4 K to 19.9 K (+2.63 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Sell | S | 95.00 | 3,330 | 316,361 | 19,374 | 22.7 K to 19.4 K (-14.67 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 30.28 | 146 | 4,421 | 22,704 | 22.6 K to 22.7 K (+0.65 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 28.55 | 600 | 17,130 | 22,558 | 22 K to 22.6 K (+2.73 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 30.28 | 619 | 18,743 | 21,958 | 21.3 K to 22 K (+2.90 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 37.68 | 1,198 | 45,141 | 21,339 | 20.1 K to 21.3 K (+5.95 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 28.55 | 220 | 6,281 | 20,141 | 19.9 K to 20.1 K (+1.10 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 35.18 | 547 | 19,243 | 19,921 | 19.4 K to 19.9 K (+2.82 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Option Exercise | M | 16.28 | 10,000 | 162,800 | 0 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Sell | S | 96.00 | 10,000 | 960,000 | 14,216 | 24.2 K to 14.2 K (-41.30 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Buy | M | 16.28 | 10,000 | 162,800 | 24,216 | 14.2 K to 24.2 K (+70.34 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Option Exercise | M | 28.41 | 2,000 | 56,820 | 7,000 | |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Sell | S | 95.00 | 2,000 | 190,000 | 14,890 | 16.9 K to 14.9 K (-11.84 %) |
Apr 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Buy | M | 28.41 | 2,000 | 56,820 | 16,890 | 14.9 K to 16.9 K (+13.43 %) |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 35.18 | 803 | 28,250 | 19,250 | |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 796 | 29,993 | 28,649 | |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 583 | 21,967 | 21,000 | |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 32.07 | 1,214 | 38,933 | 18,544 | |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 30.28 | 656 | 19,864 | 7,875 | |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 89.16 | 803 | 71,596 | 34,618 | 35.4 K to 34.6 K (-2.27 %) |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 35.18 | 803 | 28,250 | 35,421 | 34.6 K to 35.4 K (+2.32 %) |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 89.16 | 1,379 | 122,952 | 34,618 | 36 K to 34.6 K (-3.83 %) |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 796 | 29,993 | 35,997 | 35.2 K to 36 K (+2.26 %) |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 583 | 21,967 | 35,201 | 34.6 K to 35.2 K (+1.68 %) |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 89.19 | 1,870 | 166,790 | 34,618 | 36.5 K to 34.6 K (-5.12 %) |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 32.07 | 1,214 | 38,933 | 36,488 | 35.3 K to 36.5 K (+3.44 %) |
Apr 10 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 30.28 | 656 | 19,864 | 35,274 | 34.6 K to 35.3 K (+1.89 %) |
Apr 09 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Option Exercise | M | 25.30 | 2,500 | 63,250 | 2,500 | |
Apr 09 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Sell | S | 86.00 | 1,200 | 103,200 | 8,965 | 10.2 K to 9 K (-11.81 %) |
Apr 09 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Sell | S | 86.00 | 2,500 | 215,000 | 10,165 | 12.7 K to 10.2 K (-19.74 %) |
Apr 09 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Buy | M | 25.30 | 2,500 | 63,250 | 12,665 | 10.2 K to 12.7 K (+24.59 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 86.14 | 2,335 | 201,137 | 34,618 | 37 K to 34.6 K (-6.32 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 86.14 | 808 | 69,601 | 36,953 | 37.8 K to 37 K (-2.14 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 91.78 | 1,500 | 137,670 | 37,761 | 39.3 K to 37.8 K (-3.82 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 89.60 | 572 | 51,251 | 39,261 | 39.8 K to 39.3 K (-1.44 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Option Exercise | M | 20.03 | 10,000 | 200,300 | 0 | |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Option Exercise | M | 32.77 | 10,000 | 327,700 | 0 | |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Option Exercise | M | 15.15 | 5,000 | 75,750 | 0 | |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Sell | S | 92.36 | 4,363 | 402,967 | 6,600 | 11 K to 6.6 K (-39.80 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Sell | S | 91.38 | 18,637 | 1,703,049 | 10,963 | 29.6 K to 11 K (-62.96 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Sell | S | 89.00 | 2,000 | 178,000 | 29,600 | 31.6 K to 29.6 K (-6.33 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Buy | M | 20.03 | 10,000 | 200,300 | 31,600 | 21.6 K to 31.6 K (+46.30 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Buy | M | 32.77 | 10,000 | 327,700 | 21,600 | 11.6 K to 21.6 K (+86.21 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Buy | M | 15.15 | 5,000 | 75,750 | 11,600 | 6.6 K to 11.6 K (+75.76 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Option Exercise | M | 28.55 | 3,502 | 99,982 | 5,247 | |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Option Exercise | M | 29.03 | 13,776 | 399,917 | 0 | |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Buy | M | 28.55 | 3,502 | 99,982 | 131,198 | 127.7 K to 131.2 K (+2.74 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Buy | M | 29.03 | 13,776 | 399,917 | 127,696 | 113.9 K to 127.7 K (+12.09 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Sell | S | 90.81 | 1,300 | 118,053 | 113,920 | 115.2 K to 113.9 K (-1.13 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Sell | S | 89.30 | 8,405 | 750,567 | 115,220 | 123.6 K to 115.2 K (-6.80 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Sell | S | 86.14 | 7,859 | 676,974 | 123,625 | 131.5 K to 123.6 K (-5.98 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Sell | S | 86.14 | 3,770 | 324,748 | 131,484 | 135.3 K to 131.5 K (-2.79 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | Lasowski Juergen | EVP, Corp. Dev & St ... | Sell | S | 86.14 | 1,164 | 100,267 | 36,265 | 37.4 K to 36.3 K (-3.11 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | Lasowski Juergen | EVP, Corp. Dev & St ... | Sell | S | 86.13 | 711 | 61,238 | 37,429 | 38.1 K to 37.4 K (-1.86 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | Lasowski Juergen | EVP, Corp. Dev & St ... | Sell | S | 86.14 | 776 | 66,845 | 38,140 | 38.9 K to 38.1 K (-1.99 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Option Exercise | M | 23.70 | 10,000 | 237,000 | 0 | |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Sell | S | 92.00 | 10,000 | 920,000 | 14,216 | 24.2 K to 14.2 K (-41.30 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Buy | M | 23.70 | 10,000 | 237,000 | 24,216 | 14.2 K to 24.2 K (+70.34 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Sell | S | 89.62 | 1,767 | 158,359 | 27,066 | 28.8 K to 27.1 K (-6.13 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Sell | S | 86.15 | 2,066 | 177,986 | 28,833 | 30.9 K to 28.8 K (-6.69 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Sell | S | 86.14 | 2,694 | 232,061 | 51,551 | 54.2 K to 51.6 K (-4.97 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Sell | S | 86.13 | 1,167 | 100,514 | 54,245 | 55.4 K to 54.2 K (-2.11 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Sell | S | 86.14 | 466 | 40,141 | 47,646 | 48.1 K to 47.6 K (-0.97 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Sell | S | 86.15 | 907 | 78,138 | 19,374 | 20.3 K to 19.4 K (-4.47 %) |
Apr 03 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Payment of Exercise | F | 88.86 | 438 | 38,921 | 20,281 | 20.7 K to 20.3 K (-2.11 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Option Exercise | A | 88.86 | 5,900 | 524,274 | 5,900 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | GRILLO LOPEZ ANTONIO J | Director | Grant | A | 0.00 | 2,100 | 0 | 6,600 | 4.5 K to 6.6 K (+46.67 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Option Exercise | A | 88.86 | 5,900 | 524,274 | 5,900 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Grant | A | 0.00 | 2,100 | 0 | 14,216 | 12.1 K to 14.2 K (+17.33 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Option Exercise | A | 88.86 | 5,900 | 524,274 | 5,900 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Grant | A | 0.00 | 2,100 | 0 | 14,890 | 12.8 K to 14.9 K (+16.42 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Option Exercise | A | 88.86 | 24,300 | 2,159,298 | 24,300 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Torley Helen | EVP, Chief Commerci ... | Grant | A | 0.00 | 8,600 | 0 | 48,112 | 39.5 K to 48.1 K (+21.77 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Nevinny Corinne H | Director | Option Exercise | A | 88.86 | 5,900 | 524,274 | 5,900 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Nevinny Corinne H | Director | Grant | A | 0.00 | 2,100 | 0 | 9,600 | 7.5 K to 9.6 K (+28.00 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | A | 88.86 | 7,000 | 622,020 | 7,000 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Grant | A | 0.00 | 2,500 | 0 | 20,719 | 18.2 K to 20.7 K (+13.72 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Lasowski Juergen | EVP, Corp. Dev & St ... | Option Exercise | A | 88.86 | 20,100 | 1,786,086 | 20,100 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Lasowski Juergen | EVP, Corp. Dev & St ... | Grant | A | 0.00 | 7,100 | 0 | 38,916 | 31.8 K to 38.9 K (+22.32 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | A | 88.86 | 16,700 | 1,483,962 | 16,700 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Grant | A | 0.00 | 6,000 | 0 | 39,833 | 33.8 K to 39.8 K (+17.73 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Option Exercise | A | 88.86 | 5,900 | 524,274 | 5,900 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Grant | A | 0.00 | 2,100 | 0 | 10,165 | 8.1 K to 10.2 K (+26.04 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | RINGO WILLIAM R | Director | Option Exercise | A | 88.86 | 5,900 | 524,274 | 5,900 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | RINGO WILLIAM R | Director | Grant | A | 0.00 | 2,100 | 0 | 9,837 | 7.7 K to 9.8 K (+27.14 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Option Exercise | A | 88.86 | 15,100 | 1,341,786 | 15,100 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Foster-Cheek Kaye I | SVP, Global Human R ... | Grant | A | 0.00 | 5,400 | 0 | 30,899 | 25.5 K to 30.9 K (+21.18 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | WIERENGA WENDALL | Director | Option Exercise | A | 88.86 | 5,900 | 524,274 | 5,900 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | WIERENGA WENDALL | Director | Grant | A | 0.00 | 2,100 | 0 | 11,180 | 9.1 K to 11.2 K (+23.13 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Option Exercise | A | 88.86 | 22,600 | 2,008,236 | 22,600 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Grant | A | 0.00 | 8,000 | 0 | 55,412 | 47.4 K to 55.4 K (+16.87 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Option Exercise | A | 88.86 | 75,300 | 6,691,158 | 75,300 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Option Exercise | M | 35.18 | 10,938 | 384,799 | 54,687 | |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Grant | A | 0.00 | 26,800 | 0 | 135,254 | 108.5 K to 135.3 K (+24.71 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Sell | S | 90.00 | 10,938 | 984,420 | 108,454 | 119.4 K to 108.5 K (-9.16 %) |
Apr 01 2013 | ONXX | ONYX PHARMACEUTICA ... | COLES N ANTHONY | Chairman & CEO | Buy | M | 35.18 | 10,938 | 384,799 | 119,392 | 108.5 K to 119.4 K (+10.09 %) |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | CAGNONI PABLO J | EVP, Global R&D and ... | Option Exercise | A | 87.83 | 34,030 | 2,988,855 | 34,030 | |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | CAGNONI PABLO J | EVP, Global R&D and ... | Grant | A | 0.00 | 16,257 | 0 | 16,257 | 0 to 16.3 K |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 37.68 | 1,198 | 45,141 | 20,364 | |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 35.18 | 547 | 19,243 | 13,307 | |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 30.28 | 766 | 23,194 | 7,910 | |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Option Exercise | M | 28.55 | 820 | 23,411 | 2,393 | |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Sell | S | 85.65 | 3,331 | 285,300 | 18,219 | 21.6 K to 18.2 K (-15.46 %) |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 37.68 | 1,198 | 45,141 | 21,550 | 20.4 K to 21.6 K (+5.89 %) |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 35.18 | 547 | 19,243 | 20,352 | 19.8 K to 20.4 K (+2.76 %) |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 30.28 | 766 | 23,194 | 19,805 | 19 K to 19.8 K (+4.02 %) |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | WOOD JULIANNA R | VP, Public Affairs | Buy | M | 28.55 | 820 | 23,411 | 19,039 | 18.2 K to 19 K (+4.50 %) |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Option Exercise | M | 38.85 | 5,000 | 194,250 | 0 | |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Sell | S | 88.00 | 5,000 | 440,000 | 12,116 | 17.1 K to 12.1 K (-29.21 %) |
Mar 13 2013 | ONXX | ONYX PHARMACEUTICA ... | LUNDBERG MAGNUS | Director | Buy | M | 38.85 | 5,000 | 194,250 | 17,116 | 12.1 K to 17.1 K (+41.27 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Option Exercise | M | 27.63 | 2,000 | 55,260 | 8,000 | |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Sell | S | 85.00 | 2,000 | 170,000 | 8,065 | 10.1 K to 8.1 K (-19.87 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Buy | M | 27.63 | 2,000 | 55,260 | 10,065 | 8.1 K to 10.1 K (+24.80 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Option Exercise | M | 28.41 | 1,000 | 28,410 | 9,000 | |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Sell | S | 85.00 | 1,000 | 85,000 | 12,790 | 13.8 K to 12.8 K (-7.25 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | GODDARD PAUL | Director | Buy | M | 28.41 | 1,000 | 28,410 | 13,790 | 12.8 K to 13.8 K (+7.82 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 796 | 29,993 | 29,445 | |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 37.68 | 584 | 22,005 | 21,583 | |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 35.18 | 802 | 28,214 | 20,053 | |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 30.28 | 657 | 19,894 | 8,531 | |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Option Exercise | M | 32.07 | 1,215 | 38,965 | 19,758 | |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Sell | S | 79.72 | 4,054 | 323,185 | 33,833 | 37.9 K to 33.8 K (-10.70 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 796 | 29,993 | 37,887 | 37.1 K to 37.9 K (+2.15 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 37.68 | 584 | 22,005 | 37,091 | 36.5 K to 37.1 K (+1.60 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 35.18 | 802 | 28,214 | 36,507 | 35.7 K to 36.5 K (+2.25 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 30.28 | 657 | 19,894 | 35,705 | 35 K to 35.7 K (+1.87 %) |
Mar 11 2013 | ONXX | ONYX PHARMACEUTICA ... | SHEMA SUZANNE M | EVP, GC and Corp. S ... | Buy | M | 32.07 | 1,215 | 38,965 | 35,048 | 33.8 K to 35 K (+3.59 %) |
Mar 05 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Option Exercise | M | 25.30 | 2,500 | 63,250 | 5,000 | |
Mar 05 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Sell | S | 77.20 | 2,500 | 193,000 | 8,065 | 10.6 K to 8.1 K (-23.66 %) |
Mar 05 2013 | ONXX | ONYX PHARMACEUTICA ... | WIGGANS THOMAS G | Director | Buy | M | 25.30 | 2,500 | 63,250 | 10,565 | 8.1 K to 10.6 K (+31.00 %) |
Mar 05 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Option Exercise | M | 34.48 | 2,211 | 76,235 | 51,719 | |
Mar 05 2013 | ONXX | ONYX PHARMACEUTICA ... | Fust Matthew K | EVP & Chief Financi ... | Buy | M | 34.48 | 2,211 | 76,235 | 47,412 | 45.2 K to 47.4 K (+4.89 %) |